Gaucher disease and comorbidities: B-cell malignancy and parkinsonism

American Journal of Hematology

Volumn 90, Issue S1, 2015, Pages S25-S28

  Cox, Timothy M ^a   Rosenbloom, Barry E ^b   Barker, Roger A ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Cedars Sinai Tower Hematology Oncology   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; HYDROLASE; INTERLEUKIN 6; PARAPROTEIN; SPHINGOSINE;

B CELL LYMPHOMA; B LYMPHOCYTE; CANCER INCIDENCE; CAUSE OF DEATH; CELL PROLIFERATION; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DEACYLATION; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME THERAPY; GAUCHER DISEASE; GENE MUTATION; GENETIC RISK; HUMAN; IMMUNOREGULATION; LEWY BODY; MACROPHAGE ACTIVATION; MODIFIER GENE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NATURAL KILLER T CELL; NONHODGKIN LYMPHOMA; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPLENECTOMY; UNFOLDED PROTEIN RESPONSE; ENZYMOLOGY; PATHOLOGY;

COMORBIDITY; GAUCHER DISEASE; HUMANS; LYMPHOMA, B-CELL; PARKINSONIAN DISORDERS;

EID: 84932148155     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24057     Document Type: Review

References (51)

1. Brautbar A, Elstein D, Pines G, et al. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol Dis 2004;32:214-217.
2. de Fost M, Out TA, de Wilde FA, et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: Data from an adult cohort of 63 patients and review of the literature. Ann Hematol 2008;87:439-449.
3. Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: A study from the Gaucher Registry. Blood 2005;105:4569-4572.
4. Zimran A, Liphshitz I, Barchana M, et al. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 2005;34:197-200.
5. de Fost M, Vom Dahl S, Weverling GJ, et al. Increased incidence of cancer in adult Gaucher disease in western Europe. Blood Cells Mol Dis 2006;36:53-58.
6. Therneau T, Kyle R, Melton LR, et al. Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc 2012;87:1071-1079.
7. Landgren O, Turesson I, Gridley G, Caporaso NE. Risk of malignant disease among 1525 adult male US veterans with Gaucher disease. Arch Intern Med 2007;167:1189-1194.
8. Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 2009;84:208-214.
9. Bertam H, Eldibany M, Padgett J, Dragon L. Splenic lymphoma arising in a patient with Gaucher disease. A case report and review of the literature. Arch Path Lab Med 2003;127:e242-245.
10. Dekker N, Dussen L, Hollak C, et al. Elevated plasma glucosphingosine in Gaucher disease: Relation to phenotype, storage cell markers, and therapeutic response. Blood 2011;118:e118-127.
11. Hannun Y, Obeid L. Principles of bioactive lipid signaling: Lessons from sphingolipids. Nat Rev Mol Cell Biol 2008;9:139-150.
12. Barth B, Shanugavelandy S, Taclosky D, et al. Gaucher's disease and cancer: A sphingolipid perspective. Crit Rev Oncog 2013;18:221-234.
13. Boven LA, van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 2004;122:359-369.
14. Cheung W, van Ness B. Distinct interleukin-6 signal transduction leads to growth arrest and death in B-cells or growth promotion and cell survival in myeloma cells. Leukemia 2002;16:1182-1188.
15. Ayto R, Hughes D. Gaucher disease and myeloma. Crit Rev Oncog 2013;18:247-268.
16. Nair S, Boddupalli C, Verma R, et al. Type II NKT-TFH cells against Gaucher lipids regulate B cell immunity and inflammation. Blood 2015;125:1256-1271.
17. Beutler E. Gaucher disease as a paradigm of current issues regarding single gene mutations of humans. Proc Natl Acad Sci USA 1993;90:5384-5390.
18. Allen MJ, Myer BJ, Khokher AM, et al. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: Increased release of interleukin-6 and interleukin-10. QJM 1997;90:19-25.
19. Mistry P, Taddei T, Vom Dahl S, Rosenbloom B. Gaucher disease and malignancy: A model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog 2013;18:235-246.
20. Fleshner P, Aufses AJ, Grabowski G, Elias R. A 27 year experience with splenectomy for Gaucher's disease. Am J Surg 1991;161:69-75.
21. Mellemkjoer LOJ, Liet MS, Gridley G, Mclaughlin JK. Cancer risk after splenectomy. Cancer 1995;75:577-583.
22. Pavlova E, Wang S, Archer J, et al. Cell lymphoma and myeloma in murine Gaucher disease. J Pathol 2013;231:88-97.
23. Cox T. Gaucher disease: Clinical profile and therapeutic developments. Biologics 2010;4:299-313.
24. Pavlova E, Archer J, Wang S, et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J Pathol 2015;235:113-124.
25. Beutler E, Grabowski G. Gaucher disease. In: Scriver C, Beaudet A, Sly W, Valle D, editors. Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001. pp 3635-3668.
26. Rosenbloom B, Balwani M, Bronstein JM, et al. The incidence of parkinsonism in patients with type 1 Gaucher disease: Data from the ICGG Gaucher Registry. Blood Cells Mol Dis 2011;46:95-102.
27. Biegstraaten M, Mengel E, Marodi L, et al. Peripheral neuropathy in adult type 1 Gaucher disease: A 2-year prospective observational study. Brain 2010;133:2909-2919.
28. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol 2012;11:986-998.
29. Goker-Alpan O, Schiffmann R, LaMarca ME, et al. Parkinsonism among Gaucher disease carriers. J Med Genet 2004;41:937-940.
30. Nichols WC, Pankratz N, Marek DK, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009;72:310-316.
31. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661.
32. Gan-Or ZAI, Kilarski LL, Bar-Shira A, et al. Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology 2015;84:880-887.
33. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009;132(Pt 7):1783-1794.
34. Goker-Alpan O, Giasson BI, Eblan MJ, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006;67:908-910.
35. Tsuang DLJ, Lopez OL, Hamilton RL, et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology 2012;79:1944-1950.
36. McNeill AWR, Tzen KY, Aguiar PC, et al. Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. PLoS One 2013;8:e69190.
37. Brockmann K, Hilker R, Pilatus U, et al. GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology 2012;79:213-220.
38. Winder-Rhode SS, Evans J, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013;136:392-399.
39. Gegg M, Burke D, Heales S, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol 2012;72:455-463.
40. Westbroek W, Gustafson A, Sidransky E. Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends Mol Med 2011;17:485-493.
41. Goker-Alpan O, Stubblefield B, Giasson B, Sidransky E. Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders. Acta Neuropathol 2010;120:641-649.
42. Mazzulli J, Xu Y, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37-52.
43. McNeill A, Magalhaes J, Shen C, et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 2014;137(Pt 5):1481-1495.
44. Dermentzaki G, Dimitriou E, Xilouri M, et al. Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells. PLoS One 2013;8:e60674.
45. Cleeter MWCK, Gluck C, Mehta A, et al. Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int 2013; 62:1-7.
46. Osellame L, Rahim A, Hargreaves I, et al. Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease. Cell Metab 2013;17:941-953.
47. Barrès R, Osler M, Yan J, et al. Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell Metab 2009;10:189-198.
48. Zheng B, Liao Z, Locascio J, et al. Global PD gene expression (GPEX) consortium. PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2010;2:52ra73.
49. Ron I, Rapaport D, Horowitz M. Interaction between parkin and mutant glucocerebrosidase variants: A possible link between Parkinson disease and Gaucher disease. Hum Mol Gene 2010;19:3771-3781.
50. Kurzawa-Akanbi MHP, Blain PG, Lett DJ, et al. Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease. J Neurochem 2012;123:298-309.
51. Gahl W. The battlefield of rare diseases: Where uncommon insights are common. Sci Transl Med 2012;4:154ed157